Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.50 |
| ▸ | RXRB | P28702 | 7/20 | 0.50 |
| ▸ | RXRG | P48443 | 7/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6231234 | 0.77 | RXRA (0.46) | RXRARXRBRXRGGABRA1GABRB2 | |
| SCHEMBL90526 | 0.75 | ALDH1A1 (0.33) | — | |
| SCHEMBL89138 | 0.73 | — | — | |
| SCHEMBL2785505 | 0.71 | RXRA (0.50) | RXRARXRBRXRGGABRA1GABRB2 | |
| SCHEMBL43496 | 0.71 | GABRA1 (0.43) | RXRARXRBRXRGGABRA1GABRB2 | |
| SCHEMBL14372107 | 0.71 | GABRA1 (0.52) | RXRARXRBRXRGGABRA1GABRB2 | |
| SCHEMBL345598 | 0.68 | GABRA1 (0.48) | RXRARXRBRXRGGABRA1GABRB2 | |
| SCHEMBL175063 | 0.67 | ALDH1A1 (0.44) | CYP2C19 | |
| SCHEMBL10430838 | 0.67 | RXRA (0.57) | RXRARXRBRXRGGABRA1GABRB2 | |
| SCHEMBL13673476 | 0.66 | GABRA1 (0.52) | RXRARXRBRXRGGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129444-B2 | Self-adhesive dental materials | 3M ESPE AG (DE) | 2012-03-06 | — | — | US | claimed |
| US-11998417-B2 | Process for producing a surface-modified dental article | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-06-04 | — | — | US | disclosed |
| US-11992539-B2 | Curable dental compositions and uses thereof | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4362881-A1 | DENTAL CEMENT COMPOSITION, KIT OF PARTS AND USE THEREOF | 3M Innovative Properties Company (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024057144-A1 | DENTAL PRODUCT WITH REDUCED EXTRUSION FORCES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230404861-A1 | CURABLE DENTAL COMPOSITIONS AND USES THEREOF | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2023-12-21 | — | — | US | disclosed |
| EP-4251117-A1 | CURABLE DENTAL COMPOSITIONS AND USES THEREOF | 3M Innovative Properties Company (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230225829-A1 | PROCESS FOR PRODUCING A SURFACE-MODIFIED DENTAL ARTICLE | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2023-07-20 | — | — | US | disclosed |
| EP-4175584-A1 | PROCESS FOR PRODUCING A SURFACE-MODIFIED DENTAL ARTICLE | 3M Innovative Properties Company (US) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023275637-A1 | DENTAL CEMENT COMPOSITION, KIT OF PARTS AND USE THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2001044338-A1 | RADICALLY CURABLE URETHANE PREPOLYMERS AND THEIR USE IN DENTAL MATERIALS | 3M ESPE AG (DE) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001018085-A1 | FILLER FOR PLASTIC FORMULATIONS BASED ON POLYURETHANE | 3M ESPE AG (DE) | 2001-03-15 | — | — | WO | disclosed |
| EP-1027377-A1 | POLYMERIZABLE COMPOSITION AND THE APPLICATION THEREOF AS A COUPLING AGENT | ESPE Dental AG (DE) | 2000-08-16 | — | — | EP | disclosed |
| US-5968998-A | ADDITIONALLY CONTAINING SPECIFIED UNSATURATED ARYL COMPOUND TO LENGTHEN SETTING TIME | ESPE STIFTUNG & CO. PRODUKTIONS-UND VERTRIEBS KG (DE) | 1999-10-19 | — | — | US | disclosed |
| WO-1999024477-A1 | POLYMERIZABLE COMPOSITION AND THE APPLICATION THEREOF AS A COUPLING AGENT | ESPE DENTAL AG (DE) | 1999-05-20 | — | — | WO | disclosed |
| US-5824720-A | DI OR MULTI(METH)ACRYLATES, INITIATORS, ACTIVATORS, FILLERS AND FLUORIDE COMPLEXES FOR DENTAL FILLING | THERA PATENT GMBH & CO. KG GESELLSCHAFT FUR INDUSTRIELLE SCHUTZRECHTE (DE) | 1998-10-20 | — | — | US | disclosed |
| US-5583164-A | FREE RADICAL POLYMERIZATION; DELAY CURING | ESPE STIFTUNG & CO. PRODUKTIONS-UND VERTRIEBS KG (DE) | 1996-12-10 | — | — | US | disclosed |
| EP-0717977-A2 | Fluoride releasing dental composite material | THERA Patent GmbH & Co. KG Gesellschaft für industrielle Schutzrechte (DE) | 1996-06-26 | — | — | EP | disclosed |
| EP-0374824-B1 | DENTAL COMPOSITIONS CONTAINING BIFUNCTIONAL ACRYLIC OR METHACRYLIC ACID ESTERS | THERA Patent GmbH & Co. KG Gesellschaft für industrielle Schutzrechte (DE) | 1993-09-22 | — | — | EP | disclosed |
| US-4131729-A | Dental compositions comprising acrylic esters of tricyclo [5.2.1.02,6 ] decane polymers | ESPE FABRIK PHARMAZEUTISCHER PRAPARATE GMBH (DE) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230404861-A1 | CURABLE DENTAL COMPOSITIONS AND USES THEREOF | H1-0, COL1A1, HAX1 | RXRA 191/4885RXRB 317/4885RXRG 206/4885 |
| US-11992539-B2 | Curable dental compositions and uses thereof | H1-0, COL1A1, HAX1 | RXRA 191/4885RXRB 317/4885RXRG 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.